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Abstract Recent studies in multiple epithelial cancers
have shown that the inhibitory receptor programmed cell
death 1 (PD-1) is expressed on tumor-infiltrating lympho-
cytes and/or programmed death ligand 1 (PD-L1) is
expressed on tumor cells, suggesting that antitumor
immunity may be modulated by the PD-1/PD-L1 signaling
pathway. In addition, phase 1 clinical trials with mono-
clonal antibodies targeting PD-1 or PD-L1 have shown
promising results in several human cancers. The purpose of
this study was to investigate the impact of PD-L1 expres-
sion in human breast cancer specimens. We conducted an
immunohistochemistry study using a tissue microarray
encompassing 650 evaluable formalin-fixed breast cancer
cases with detailed clinical annotation and outcomes data.
PD-L1 was expressed in 152 (23.4 %) of the 650 breast
cancer specimens. Expression was significantly associated
with age, tumor size, AJCC primary tumor classification,
tumor grade, lymph node status, absence of ER expression,
and high Ki-67 expression. In univariate analysis, PD-L1
expression was associated with a significantly worse OS. In
multivariate analysis, PD-L1 expression remained an
independent negative prognostic factor for OS. In subset
analyses, expression of PD-L1 was associated with sig-
nificantly worse OS in the luminal B HER2- subtype, the
luminal B HER2? subtype, the HER2 subtype, and the
basal-like subtype. This is the first study to demonstrate
that PD-L1 expression is an independent negative prog-
nostic factor in human breast cancer. This finding has
important implications for the application of antibody
therapies targeting the PD-1/PD-L1 signaling pathway in
this disease.
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Introduction
T cells play a critical role in the human immune system,
recognizing foreign antigens and orchestrating an effective
immune reaction. However, despite the ability to recognize
tumor-associated antigens, T cells are often unable to
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mediate tumor regression [1]. The interaction between T
cells and antigen-presenting cells (APC) is complex and
involves the T cell receptor and multiple co-stimulatory
receptors, which exert both activating and inhibitory
stimuli to the T cell. The interplay between activating and
inhibitory signals is especially important in modulating the
immune system’s ability to distinguish self from nonself
and to prevent autoimmune reactions [2, 3]. Programmed
cell death 1 (PD-1), a member of the CD28/CTLA-4 family
of co-stimulatory receptors, conveys an inhibitory signal to
the T cell and thus impedes immune responses. PD-1
contributes to the immune tolerance of self antigens by
peripheral T cells [2, 3]. PD-1 is expressed on natural killer
cells, dendritic cells (DCs), activated monocytes as well as
on B cells, and T cells [4–6]. Persistent high-level PD-1
expression on antigen-experienced CD8? T cells leads to a
CD8? T cell phenotype characterized by impaired effector
function and persistent expression of inhibitory receptors,
termed ‘‘T cell exhaustion’’ [7]. PD-1 has two ligands,
programmed death ligand 1 (PD-L1) and programmed
death ligand 2 (PD-L2) [8]. PD-L1 is expressed not only on
APC, DCs, as well as on activated monocytes and B cells,
but also on nonlymphoid tissues of different organs [8, 9].
Of note, expression of PD-L1 has been discovered in a
variety of epithelial cancers such as non-small cell lung
carcinoma (NSCLC) [10], pancreatic cancer [11], esopha-
geal cancer [12], squamous cell carcinomas of the head and
neck, and renal cell carcinoma (RCC) [13]. Recent evi-
dence suggests that activation of the PD-1/PD-L1 pathway
represents one mechanism allowing tumors to elude the
host’s immune system [14, 15]. The expression of PD-L1
has been associated with poor prognosis and fewer tumor-
infiltrating lymphocytes (TIL) in pancreatic cancer and
RCC [11, 16, 17]. The exertion of this pathway by cancer
cells might also explain why, in ongoing studies investi-
gating cancer vaccinations, there is no tumor growth con-
trol despite the induction of cancer-specific T cells [18–20].
These observations provide strong rationale for targeting
PD-1 or its ligand PD-L1 with antibodies capable of
inhibiting this pathway. Preclinical murine and ex vivo
studies with anti-PD-1 antibodies have shown promising
results, demonstrating that PD-1 blockade in combination
with antitumor immunotherapy can prolong survival of
mice inoculated with live melanoma cells [21]. In addition,
PD-1 blockade results in an increase of antigen-specific
cytotoxic T cells in melanoma in vitro [21–23]. Based on
these data, early phase human clinical trials targeting the
PD-1/PD-L1 pathway are currently under way for multiple
human cancers [25, 28]. Phase I clinical trials have been
conducted using the human anti-PD-1 antibody (BMS-
936558 also known as Nivolumab) demonstrating objective
responses (response rates 6–38 %) in patients with
NSCLC, advanced melanoma, RCC, and castration resis-
tant prostate cancer [24–27].
A multicenter phase I trial with a human anti-PD-L1
antibody (BMS-936559) in advanced human cancers
showed durable tumor regression (objective response rate
6–17 %) and prolonged stabilization of disease [28]. In this
clinical trial, success was documented in cancers that have
previously been considered resistant to immunotherapy,
such as NSCLC and RCC. Some of these responses were
durable, suggesting that targeting the PD-1/PD-L1 signal-
ing pathway is likely to develop into an important treat-
ment modality for patients with advanced cancer.
Since breast cancer is the most common carcinoma in
women, and the second most common cause of cancer
death among women worldwide [29], defining the impor-
tance of the PD-1/PD-L1 signaling pathway in breast
cancer is of significant clinical relevance.
Although breast cancer is commonly thought to be less
immunogenic than melanoma or RCC, there is increasing
evidence of a dynamic crosstalk between the immune
system and breast cancer. Recent studies have revealed the
presence of regulatory T cells in peripheral blood as well as
in the tumors of breast cancer patients [30, 31]. Further-
more, inhibitory molecules of the CD28 receptor family are
upregulated on breast cancer-specific T cells [32–34], and
PD-L1 is expressed on breast cancer cells [34].
We have recently shown that the presence of PD-
1? tumor infiltrating lymphocytes (TIL) is associated with
adverse clinicopathological features and is an independent
negative prognostic factor in human breast cancer [35]. We
also found a significant difference in the presence of PD-
1? TIL in the intrinsic breast cancer subtypes, as specified
by the St. Gallen consensus conference [35, 36].
Ghebeh et al. [34] demonstrated that PD-L1 is expressed
in primary breast cancer specimens (either on the cancer
cells themselves or by TIL) yet not in healthy adjoining
tissue from the same breast. They found PD-L1 expression
by tumor cells in 34 % of their cases and showed that PD-
L1 is significantly correlated with grade 3 tumors [33, 34,
37]. In a second study, the same authors also demonstrated
a correlation between expression of PD-L1by tumor cells
and a high expression of Ki-67 as well as absence of
estrogen-receptor (ER) and progesterone-receptor (PR)
expression [37].
These data strongly suggest a potential association
between activation of the PD-1/PD-L1 pathway in breast
cancer and poor prognosis. The promising results of the
phase I clinical trials targeting this pathway suggest that
these therapies could be successful in human breast cancer,
particularly in patients with clinically advanced disease, or
in patients with ER-and/or PR-negative subtypes, which
generally have a poorer prognosis [36, 38].
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However, recent data from a study looking at in situ
tumor PD-L1 mRNA expression suggests that PD-L1
expression may be associated with an increase in the
number of TIL, suggesting an association with improved
prognosis [39]. Clearly, further study is required to define
the role of PD-L1 expression in breast cancer.
To further explore the impact of PD-L1 expression in
human breast cancer, we conducted an immunohisto-
chemistry study using a breast cancer tissue microarray
(TMA) encompassing a total of 1,460 formalin-fixed breast
cancer cases with detailed clinical annotation and outcomes
data. The aim of our study was to investigate the
expression of PD-L1 by breast cancer cells and its asso-
ciation with the expression of PD-1 by TIL as well as with
clinicopathological parameters, with a particular focus on
any potential association with prognosis. The data is
reported according to the reporting recommendations for
tumor marker prognostic studies (remark) [40].
Materials and methods
Tissue microarray
We used a TMA encompassing 1,460 breast cancer tissue
punches from formalin-fixed and paraffin-embedded
tumor samples collected from patients diagnosed with
primary breast cancer between 1985 and 2007 at the
Institute for Pathology, University of Basel and the Vi-
ollier Institute in Basel, Switzerland. Of these 1,460 tissue
punches, due to the tissue loss or lack of breast cancer
tissue on individual punches, a total of 650 were evalu-
able for our study. The tissue samples were brought into a
TMA format as previously described [41]. Histopatho-
logic data were obtained from the pathology reports, and
raw patient survival data was obtained from the Cancer
Registry of Basel or from the patient’s attending physi-
cian. Retrieval of tissue and clinical data was performed
according to the regulations of the local institutional
review boards and data safety laws with specific regard to
ethical standards and patient confidentiality. The mean
follow-up time was 65 months (range 1–174 months), and
the mean age of the patients at diagnosis was 64 years
(range 27–101 years). Demographic information of the
patients is given in Table 1.
Immunohistochemistry
For immunohistochemical staining, 4-lm sections of the
TMA blocks were incubated for 30 min with a prediluted
rabbit-anti-human PD-L1 polyclonal antibody (Abcam,
Cambridge, UK) after heat-induced antigen retrieval with
Cell Conditioning Solution (Ventana Medical Systems,
Tuscon, AZ, USA). Standard DAB-technique (Optiview
DAB IHC Detection Kit, Ventana Medical Systems, Tus-
con, AZ, USA) was employed for immunostaining.
Counterstaining was performed with hematoxylin solution.
Since PD-L1 is expressed on the cell membrane as well as
the endomembrane system, membranous as well as cyto-
plasmic staining was considered positive (Fig. 1). Fre-
quency and staining intensity of PD-L1 by tumor cells were
analyzed, and PD-L1 expression was quantified using the
modified Histo-score (H-score) [42], with a range of pos-
sible scores from 0 to 300. PD-L1 expression was dichot-
omized into two groups according to the frequency
Table 1 Basic demographic data for 650 evaluable breast cancer
cases
Mean tumor size (mm)
± standard deviation (SD)
29.6 ± 16.8
Mean age at diagnosis (years)
± standard deviation (SD)
63.8 ± 14.2
Number
(n)
Percent
(%)
Tumor stage
pT1 181 27.9
pT2 350 53.8
pT3 35 5.4
pT4 84 12.9
Lymph node involvement
pN0 355 54.7
pN1 226 34.8
pN2 68 10.5
Tumor grade
1 143 22
2 259 39.8
3 248 38.2
Histologic subtype
Invasive ductal 482 76.4
Invasive lobular 72 11.4
Mucinous 23 3.6
Apocrine 3 0.5
Cribriform 14 2.2
Papillary 8 1.3
Medullary 29 4.6
Intrinsic subtype
Luminal A (ER? and/or
PR?, HER2-, Ki-67 \ 14 %)
83 12.8
Luminal B (HER2-negative) (ER?
and/or PR?, HER2-, Ki-67 C 14 %)
309 47.7
Luminal B (HER2-positive) (ER?
and/or PR?, HER2?)
73 11.3
HER2 type (ER- or PR-, HER2?) 56 8.6
Basal-like (ER-, PR-, HER2-) 127 19.6
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distributions of the H-scores, using a cut-off score of C100
(H-score 0–99 = negative/low expression, and
100–300 = positive expression). The staining intensity of
ER, PR, and HER2 was scored as described previously
[43].
Flow cytometry of human breast cancer specimens
Tumor cells suspension was derived from freshly excised
human breast cancer specimens, obtained from consenting
patients undergoing surgical treatment at Basel University
Hospital. Tissues were cut into small pieces (1 mm 9
1 mm) and digested in serum-free DMEM (GIBCO), sup-
plemented with collagenase IV (Worthington, New Jersey,
USA) and DNAse I (Sigma-Aldrich, St.Louis, Missouri,
USA) at 37 C for 60 min. After digestion, single cell
suspension was obtained by filtration through 100-lm- and
70-lm-mesh filter. Surface phenotype was determined by
flow cytometry using the following antibodies: phycoery-
thrin-(PE) labeled anti-PD-L1 (clone MIH1), fluorescein
isothiocyanate- (FITC) labeled anti-CD3 (clone SK7), allo-
phycocyanin-(APC) labeled anti-CD4 (clone SK3), APC-
labeled anti-CD8 (clone RPA-T8), FITC-labeled anti-CD90
(clone 5E10), and APC-labeled anti-EpCAM (clone EBA-
1). All the antibodies were purchased from BD Bioscience
(San Jose, USA). Propidium iodide (PI, 0.5 lg/ml) was
added to the samples prior to analysis. Relative fluorescence
intensities were measured using a BD FACScalibur flow
cytometer (BD Biosciences) following exclusion of dead
cells based on PI incorporation. Analysis was performed
using FlowJo software (Tree Star, Portland, OR).
Statistical analysis
The distributions of patient and clinical characteristics
between tumors expressing PD-L1 and those negative for
PD-L1 were compared using Chi-square test, Wilcoxon
rank-sum test, or two-sample t test, as appropriate. Overall
survival (OS) was defined as the time from the first
Table 2 Association between PD-L1 expression and clinicopatho-
logical parameters
Clinicopathologic parameter PD-L1-
positive
PD-L1-
negative
p-
value
Mean tumor size (mm) ± SD 35.1 62.9 \.0001
Mean age at diagnosis
(years) ± SD
28.1 62.9 \.0001
(n) (%) (n) (%) \.0001
Tumor stage
pT1 25 13.8 156 86.2
pT2 82 23.4 268 76.6
pT3 15 42.9 20 57.1
pT4 30 35.7 54 64.3
Lymph node involvement \.0001
pN0 65 18.3 290 81.7
pN1 52 23.0 174 77.0
pN2 34 50.0 34 50.0
Tumor grade 0.0007
1 27 18.9 116 81.1
2 47 18.1 212 81.9
3 78 31.4 170 68.6
Estrogen-receptor 0.0020
ER? 92 20.1 365 79.9
ER- 60 31.4 131 68.6
HER2 0.0237
HER2? 40 31.0 89 69.0
HER2- 112 21.6 407 78.4
Ki67 0.0043
Ki67? 136 25.9 389 74.1
Ki67- 16 13.6 102 86.4
PD-1 \.0001
PD-1? 69 66.3 35 33.7
PD-1- 83 15.2 463 84.8
Table 3 Association between PD-L1 expression and breast cancer
intrinsic subtype
Intrinsic subtype PD-L1-
positive
PD-L1-
negative
p-
value
(n) (%) (n) (%) 0.5340
Luminal A
(ER? and/or PR?, HER2-, Ki-
67 \ 14 %)
10 12.1 73 87.9
Luminal B (HER2-negative)
(ER? and/or PR?, HER2-, Ki-
67 C 14 %)
63 20.4 246 79.6
Luminal B (HER2-positive)
(ER? and/or PR?, HER2?)
21 28.8 52 71.2
HER2 type (ER-, PR-, HER2?) 19 33.9 37 66.1
Basal-like (ER-, PR-, HER2-) 39 30.7 88 69.3
Table 4 Univariate analyses for all cases, and by intrinsic subtype,
for the effect of PD-L1 expression on overall survival
PD-L1 expression, all cases Hazard ratio (95 % CI) p value
PD-L1-positive 4.430 (3.424–5.731) \.0001
PD-L1 expression, by intrinsic subtype
Luminal A 2.693 (0.743–9.764) 0.1317
Luminal B (HER2-) 3.888 (2.651–5.704) \.0001
Luminal B (HER2?) 5.172 (2.412–11.094) \.0001
HER2 type 2.834 (1.244–6.452) 0.0131
Basal-like 4.973 (2.935–8.426) \.0001
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operation to death due to any cause. Survivors were cen-
sored at the date of last contact. Survival curves by
expression of PD-L1 were estimated using the Kaplan–
Meier product-limit method and compared by log-rank test.
Univariate Cox proportional hazard models were fit to
identify factors significantly related to OS. To assess
whether the expression of PD-L1 by tumor cells was an
independent predictor of survival, a multivariate Cox
model was constructed to adjust other patient/clinical
characteristics that were significant in the univariate anal-
yses. Two-way interaction terms between expression of
PD-L1 and other factors in the multivariate Cox model
were also assessed. All analyses were two-sided and sig-
nificance was set at a p-value of 0.05. Statistical analyses
were performed using SAS (SAS Institutes, Cary, NC).
Results
Expression of PD-L1 by tumor cells was present in a total of
152 (23.4 %) of the 650 evaluable primary breast cancers.
The expression of PD-L1 was significantly associated with
age, tumor size, AJCC primary tumor classification, tumor
grade, and lymph node status (Table 2). The expression of
PD-L1 was positively associated with Ki-67 expression
(p = 0.0043), and HER2 expression (p = 0.0237, Table 2),
and negatively associated with ER expression (p = 0.0020)
(Table 2). There was no significant association with PR
expression (p = 0.1893). There was also no significant
difference of PD-L1 expression among the different
intrinsic subtypes of breast cancer, as defined by the St
Gallen consensus conference (Table 3) [36]. The breast
cancer intrinsic subtypes were originally defined by gene
expression profiling [44, 45] but can be approximated using
immunohistochemistry for ER, PR, Ki-67, and HER2 [36,
46]. These subtypes are known to have differing epidemi-
ological risk factors, prognosis, and response to therapy
[36]. Interestingly, there was a strong correlation between
the expression of PD-L1 by tumor cells and the presence of
PD-1-positive TIL (p \ 0.001).
In univariate survival analyses, breast cancer cases
expressing PD-L1 had a significantly worse OS (HR =
4.430, p \ 0.0001, Table 4 and Fig. 2). In subset analyses by
intrinsic subtype, the expression of PD-L1 was associated
with decreased OS in the luminal B HER2- subtype,
(HR = 3.888, p \ 0.0001), the luminal B HER2? subtype
Fig. 1 Representative photographs of PD-L1 expression in breast
cancer tissue punches a Tissue punch negative for PD-L1 expression.
Magnification 9200 b Tissue punch with strong PD-L1 expression in
100 % of cells. Magnification 9200 c Same tissue punch as in
b magnification 9400. d Tissue punch with strong PD-L1 expression
in 40 % of cells. Magnification 9200
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(HR = 5.127, p \ 0.0001), the HER2 subtype (HR = 2.834,
p = 0.0131), and the basal-like subtype (HR = 4.973,
p \ 0.0001) (Table 4 and Fig. 2). Of note, there was no
association with OS in the luminal A subtype. In multivariate
analysis, after adjusting for age, grade, tumor size, lymph
node status, and intrinsic subtype, the expression of PD-L1
proved to be an independent negative prognostic factor for OS
(HR = 3.063, p \ 0.0001) (Table 5).
In a small subset of 14 cases (9.2 %), we also detected
PD-L1 expression on TIL.
To investigate the expression of PD-L1 in the tumor
microenvironment in more detail, we performed flow
cytometry of cells freshly isolated from four human breast
cancers (Fig. 3). While two of the samples were negative
for PD-L1, two (one stage I and one stage IV cancer)
showed a mean of 2.55 % of PD-L1-positive cells
(2.6–2.5 %, respectively). In the stage IV cancer, 2 % of
the cells were EpCAM?/PD-L1?, while PD-L1 expression
could not be detected on CD4? or CD8? T cells. In the
stage I cancer biopsy, no EpCAM?/PD-L1? cells could be
detected, but instead, CD4?/PD-L1? and CD8?/PD-L1?
cells (1–1.8 % of all cells, respectively) (Fig. 3).
Discussion
We found PD-L1 expression in 23.4 % of primary breast
cancer specimens. In a study analyzing tissue from 44
Fig. 2 a Kaplan–Meier
survival curve for overall
survival depending on the
expression of PD-L1 (univariate
analysis) b–f Kaplan–Meier
survival curves for overall
survival depending on the
expression of PD-L1 for the
indicated breast cancer intrinsic
subtypes
20 Breast Cancer Res Treat (2014) 146:15–24
123
patients, Ghebeh et al. [34] reported PD-L1 expression in
34 % of breast cancers. These results are comparable to our
findings, although Ghebeh et al. investigated only patients
with invasive ductal carcinoma, and used a different anti-
body clone and a different scoring system, assessing any
expression of PD-L1 by tumor cells as positive. These
differences in experimental technique may account for the
slightly higher percentage of positive specimens.
Schalper et al. [39] reported PD-L1 mRNA expression
in 58 % of their breast cancer specimens. The increase
frequency of expression might be explained by the fact that
PD-L1 mRNA expression may not always correlate with
actual protein expression.
Consistent with our results, Ghebeh et al. [34] also
reported an association between PD-L1 expression and
higher tumor grade, HER2 expression, and absence of ER
expression, however, no significant correlation with lymph
node status and patient age was found. A subsequent study
by the same group with a total of 68 cases, confirmed these
associations and also demonstrated an association between
PD-L1expression in breast cancer specimens and high Ki-
67 expression [37], which we could confirm in our larger
patient cohort. The finding that PD-L1 expression in breast
cancer specimens is associated with larger and more
aggressive tumors as well as with positive lymph node
status could indicate that activation of the PD-1/PD-L1
pathway may help these tumors evade antitumor immune
responses and consequently proliferate and spread more
rapidly.
Soliman et al. [47] investigated their PD-L1 expression
in six breast cancer cell lines by flow cytometry. They
found the highest expression in cell lines of the basal-like
intrinsic subtype, which supports our finding of an asso-
ciation between PD-L1 expression and poor prognosis in
this subtype. Soliman et al. [47] also analyzed 61 breast
cancer specimens for PD-L1 protein expression. Although
there was a suggestion that PD-L1 expression is associated
with positive lymph node status, they could not establish a
statistically significant association with any clinicopatho-
logical parameters.
The present study is the first to show that PD-L1 protein
expression in breast cancer specimens is associated with
poor prognosis in breast cancer.
In contrast, the study by Schalper et al. [39] looking at
in situ PD-L1 mRNA expression on two sets of breast
cancer TMAs, found that PD-L1 mRNA expression was
significantly associated with disease-free survival, and also
suggested an association (that did not reach statistical
significance) with longer disease-specific survival in a
cohort of 358 patients. They also found that PD-L1 mRNA
expression by breast cancer cells was associated with
increased TIL [39]. Similar results were reported by the
same group in a study analyzing NSCLC, where PD-L1
mRNA or protein expression by tumor cells was signifi-
cantly associated with better outcome [48]. In their dis-
cussion, the authors suggest that expression of PD-L1 by
tumor cells might represent antigen-induced antitumor
immune pressure, resulting in recruitment of TIL to the
tumor site, where they induce a partial antitumor effect.
Recent studies support this notion by reporting an associ-
ation between PD-L1 protein expression and longer sur-
vival in metastatic melanoma, [49] merkel cell carcinoma
[50], and colorectal carcinoma [51].
We hypothesize that the expression of PD-L1 by tumor
cells can contribute to impaired function of TIL, impeding
antitumor immunity. This would explain why PD-L1
expression is associated with poor prognosis in our study of
human breast cancers, consistent with multiple studies
looking at different human cancers such as melanoma,
renal, urothelial, gastric, lung, and colorectal cancer [38,
52–55]. This hypothesis is also consistent with the results
of recent phase I clinical trials where targeting the PD-1/
PD-L1 pathway resulted in durable tumor regression and
stabilization of disease in multiple human epithelial can-
cers [25, 27, 28]. The inconsistent results related to the
association of PD-L1 expression with clinical outcome in
some of these cancers could be based on different
Table 5 Multivariate analysis for the effect of clinicopathologic
parameters and PD-L1 expression on overall survival
Clinicopathologic parameter Hazard ratio (95 % CI) p-value
Age (per 1 year) 1.033 (1.022–1.044) \.0001
Tumor stage
pT1 (reference) 1
pT2 1.622 (1.084–2.427) 0.0186
pT3 1.621 (0.869–3.026) 0.1290
pT4 2.185 (1.334–3.578) 0.0019
Lymph node involvement
pN1 (reference) 1
pN1 1.452 (1.071–1.968) 0.0165
pN2 1.921 (1.283–2.875) 0.0015
Tumor grade
BRE grade 1 (reference) 1
2 1.874 (1.201–2.923) 0.0057
3 2.537 (1.604–4.014) \.0001
PD-L1 expression, all cases
PD-L1-negative (reference) 1
PD-L1-positive 3.063 (2.318–4.047) \.0001
PD1 expression, by intrinsic subtype
Luminal A (reference) 1
Luminal B (HER2-) 1.542 (0.874–2.724) 0.1352
Luminal B (HER2?) 1.484 (0.764–2.882) 0.2437
Her2 type 1.091 (0.530–2.247) 0.8123
Basal-like 2.394 (1.294–4.430) 0.0054
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modalities of assessment of PD-L1 expression or on the
differential impact of PD-L1 expression on different sub-
populations of TIL. In their study of 1,058 specimens,
Droeser et al. [31] showed that there are different sub-
populations of TIL depending on breast cancer subtype,
with variable impact on the prognosis. It could thus be
hypothesized that depending on the TIL subpopulations,
expression of PD-L1 by tumor cells might have a differ-
ential impact on antitumor immunity.
In our analysis, the strongest association between PD-L1
and decreased OS was found in the basal-like intrinsic sub-
type. Since treatment options are limited for this subtype, our
finding is of particular importance, and PD-1/PD-L1 blockade
might prove to be a valid treatment option in these patients.
We recently reported the expression of PD-1 on TIL to
be an independent negative prognostic factor in breast
cancer [35]. Interestingly, we found a strong correlation
between PD-L1 expression by tumor cells and the presence
of PD-1? TIL in our collective. This further suggests PD-
L1 expressed by tumor cells directly interacts with PD-
1? TIL and in turn leads to attenuation of their antitumor
activity. Our finding is also consistent with the hypothesis
that therapeutic blockade of the PD-1/PD-L1 pathway
might be a valid treatment approach in breast cancer.
Topalian et al. [25] analyzed PD-L1 protein expression
in 42 tumor specimens of patients with various malignan-
cies before treatment with anti-PD-1 antibody. They
showed that only patients whose tumors expressed PD-L1
had an objective response to the anti-PD-1 therapy.
Although these results were documented as preliminary and
without statistical significance, they support the hypothesis
that PD-L1 protein expression might constitute a predictive
biomarker and help select patients for anti-PD-1/PD-L1
therapy. While there are ongoing clinical trials targeting the
PD-1/PD-L1 signaling pathway [24–28], all of these studies
include only a limited number of breast cancer patients.
As an interesting finding using flow cytometry, we
found expression of PD-L1 on TIL in a small tumor and
predominantly on cancer cells in a larger tumor. This might
be an indication that as the tumor progresses PD-L1 is
produced in an increasing fashion by tumor cells in order to
evade the mounting antitumor immune response. Ghebeh
et al. also found PD-L1 expression by TIL in 41 % of their
specimens, predominantly on CD4 ? -T cells. Expression
of PD-L1 on TIL might inhibit T-cell function by binding
to PD-1 expressed on other TIL, as demonstrated by Seo
et al. [56]. We could also detect immunohistochemical
expression of PD-L1 on TIL in a small subset of cases
Fig. 3 Representative flow cytometry data for PD-L1 expression in human breast cancer a stage IV breast cancer b stage I breast cancer
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(9.2 %), but in light of the low case number, the impact on
prognosis was not analyzed.
We acknowledge that our study has some limitations
such as the fact that the use of TMAs may not accurately
represent PD-L1 protein expression due to intra-tumoral
heterogeneity of expression. We therefore used whole tis-
sue sections and flow cytometry to assess PD-L1 expres-
sion by tumor cells from the 4 breast cancer patients. In the
two positive sections, there was no discernible intra-
tumoral heterogeneity of PD-L1 expression, although this
was a small collective (not encompassing patients whose
tumors were included in the TMAs).
In addition, there are concerns regarding the reliability
of immunohistochemical staining for PD-L1, due to the
lack of a standardized staining and analysis protocol as
well as the variety of antibodies. The commercially avail-
able rabbit-anti-human PD-L1 polyclonal antibody used
here was validated using placental and lymph node tissue
as positive controls. Moreover, using the same antibody, in
42 patients with HCC, Cariani et al. [57] not only similarly
linked PD-L1 to a shorter OS, time to recurrence, but also
found a positive association with TIL.
Conclusion
We are the first to show that the expression of PD-L1 in
breast cancer is an independent negative prognostic factor.
Our results suggest that it could serve as an important
target for antibody-based immune therapies, especially in
the basal-like intrinsic subtype where treatment options are
limited. Further research investigating the effect of PD-L1/
PD-1 blockade in breast cancer is thus strongly needed.
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